公开(公告)号：EP2658634B1

公开(公告)日：2016-03-23

申请号：EP11817430.9

申请日：2011-12-28

Applicant: Feyecon B.V.

Inventor： HOFLAND, Gerard Willem ,  DE VRIES, Tjerk Jan ,  STOLK, Maarten

IPC: B01D53/26 ,  B01D53/28 ,  A23B7/022 ,  A23L3/42 ,  C10M133/08

CPC classification number: F26B5/00 ,  A23B7/02 ,  A23B7/0205 ,  A23B7/022 ,  A23L3/0155 ,  A23L3/3526 ,  A23L3/40 ,  A23L3/42 ,  B01D53/263 ,  B01D53/28

公开(公告)号：EP2658634A1

公开(公告)日：2013-11-06

申请号：EP11817430.9

申请日：2011-12-28

Applicant: Feyecon B.V.

Inventor： HOFLAND, Gerard Willem ,  DE VRIES, Tjerk ,  STOLK, Maarten

IPC: B01D53/26 ,  B01D53/28 ,  A23B7/022 ,  A23L3/42 ,  C10M133/08

CPC classification number: F26B5/00 ,  A23B7/02 ,  A23B7/0205 ,  A23B7/022 ,  A23L3/0155 ,  A23L3/3526 ,  A23L3/40 ,  A23L3/42 ,  B01D53/263 ,  B01D53/28

Abstract: The invention relates to a process for dehydrating a water- containing medium, said medium being a pressurized gas having a pressure of at least 0.5 MPa, said process comprising: - contacting the water-containing medium with a dry ionic liquid choline salt to dehydrate the water-containing medium; and - separating a dehydrated medium from the hydrated ionic liquid choline salt. Ionic liquid choline salts offer the advantage that they can be regenerated very easily as they are surprisingly heat-stable. Furthermore, these liquid choline salts offer the advantage that they are non-toxic and largely inert. Thus, these ionic liquid choline salts can suitably be used to dehydrate water-containing media that are subsequently employed in the production of foodstuffs, beverages, nutritional formulations, pharmaceutical preparations etc.

公开(公告)号：EP2170284B1

公开(公告)日：2011-08-24

申请号：EP08779037.4

申请日：2008-07-17

Applicant: Feyecon B.V.

Inventor： VAN ROSMALEN, Gerda Maria ,  HOFLAND, Gerard Willem

IPC: A61K9/14 ,  B01J3/00 ,  B01D9/00

CPC classification number: B01J3/008 ,  A61K9/145 ,  Y02P20/544

Abstract: The present invention relates to a method of preparing a pharmaceutical co-crystal composition, said method comprising the steps of: a. simultaneously contacting a supercritical or liquefied gas with solid particles of a pharmaceutically active component and with solid particles of a co-builder to form a co -crystallisation medium containing dissolved pharmaceutically active component and dissolved co-builder as well as solid particles of the pharmaceutically active component and solid particles of the co-builder; b. transforming the solid particles of the pharmaceutically active component and the solid particles of the co-builder into co-crystals of said pharmaceutically active component and said co-builder by keeping the supercritical or liquefied gas in a supercritical or liquid state until at least 80 wt.% of the pharmaceutically active component is incorporated in the crystal matrix of said co-crystals; and c. separating said co-crystals from the supercritical or liquefied gas wherein at least a fraction of the pharmaceutically active component and at least a fraction of the co-builder remain in an undissolved state during the co-crystallisation. The present method enables easy preparation of a pharmaceutical co-crystal composition containing virtually no solvent residue and can suitably be used to prepare co-crystals of highly labile pharmaceutically active components.